| abstract |
The present invention relates to the treatment of neurological diseases with novel cyclic peptides and peptidomimetic compounds having the ability to modulate the activity of C5a receptors. Said compound preferably acts as an antagonist of the C5a receptor and acts against the C5a receptor on polymorphonuclear leukocytes, monocytes, lymphocytes and / or macrophages. In preferred forms of the invention, neurological diseases are neurodegenerative diseases, neuroimmune diseases, diseases resulting from dysfunction of the blood brain barrier, and stroke. |